Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review

N C Daw*, 1, A J Chou2, N Jaffe1, B N Rao3,4, C A Billups5, C Rodriguez-Galindo6,7,8, P A Meyers2 and W W Huh1

1Division of Paediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; 2Department of Paediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; 3Department of Surgery, St Jude Children’s Research Hospital, Memphis, TN 38105, USA; 4Department of Surgery, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38105, USA; 5Department of Biostatistics, St Jude Children’s Research Hospital and the University of Tennessee, Memphis, TN 38105, USA; 6Department of Oncology, St Jude Children’s Research Hospital, Memphis, TN 38105, USA; and 7Department of Paediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38105, USA

Background: Late relapse and solitary lesion are positive prognostic factors in recurrent osteosarcoma.

Methods: We reviewed the records of 39 patients treated at three major centres for recurrent osteosarcoma with a single pulmonary metastasis more than 1 year after diagnosis. We analysed their outcomes with respect to clinical factors and treatment with chemotherapy.

Results: Median age at diagnosis was 14.6 years. Relapse occurred at a median of 2.5 years (range, 1.2–8.2 years) after initial diagnosis. At relapse, all patients were treated by metastasectomy; 12 (31%) patients also received chemotherapy. There was no difference in time to recurrence or nodule size between the patients who received or did not receive chemotherapy at relapse. Sixteen patients had no subsequent recurrence, 13 of whom survive without evidence of disease. The 5-year and 10-year estimates of post-relapse event-free survival (PREFS) were 33.0 ± 7.5% and 33.0 ± 9.6%, respectively, and of post-relapse survival (PRS) 56.8 ± 8.6% and 53.0 ± 11.0%, respectively. There was a trend for nodules <1.5 cm to correlate positively with PREFS (P = 0.070) but not PRS (P = 0.49). Chemotherapy at first relapse was not associated with PREFS or PRS.

Conclusion: Approximately half of the patients with recurrent osteosarcoma presenting as a single pulmonary metastasis more than 1 year after diagnosis were long-term survivors. Metastasectomy was the primary treatment; chemotherapy did not add benefit.

Despite aggressive surgery and intensive chemotherapy, osteosarcoma recurs in ~30–40% of patients initially diagnosed with non-metastatic disease (Meyer et al, 2001; Meyers et al, 1998; Meyers et al, 2005; Kempf-Bielack et al, 2005; Bacci et al, 2005; Whelan et al, 2012). The outcome of patients with recurrent osteosarcoma is generally poor, with long-term survival rates of ~20% (Ferrari et al, 2003; Hawkins and Arndt, 2003; Kempf-Bielack et al, 2005; Bacci et al, 2005a). The most common site of relapse is the lung, and 50–75% of patients with recurrent osteosarcoma initially have lung involvement only (Chi et al, 2004; Crompton et al, 2006; Gelderblom et al, 2011). Favourable prognostic indicators in recurrent disease include a longer disease-free interval from initial diagnosis to relapse, good histologic response to neoadjuvant chemotherapy in the primary tumour, a solitary lesion, and the ability to achieve a second complete surgical remission (Ferrari et al, 2003; Kempf-Bielack et al, 2005; Gelderblom et al, 2011; Leary et al, 2013). For patients with pulmonary relapse, fewer nodules, unilateral involvement, complete surgical resection, and absence of pleural disruption are favourable prognostic factors (Briccoli et al, 2005; Kempf-Bielack et al, 2005; Harting et al, 2006).

*Correspondence: Dr NC Daw; E-mail: ndaw@mdanderson.org

8Current address: Department of Paediatric Oncology, Dana-Farber/Children’s Hospital Cancer Center, Boston, MA 02215, USA

Received 3 September 2014; accepted 27 October 2014; published online 25 November 2014

© 2015 Cancer Research UK. All rights reserved 0007 – 0920/15
Although adjuvant chemotherapy is necessary for the treatment of newly diagnosed osteosarcoma, the role of chemotherapy in the treatment of recurrent disease is uncertain, especially for patients with solitary recurrent pulmonary metastasis. A study demonstrated that a disease-free interval >12 months before developing osteosarcoma lung metastasis and complete surgical metastasectomy correlated with increased overall survival (OS; Harting et al, 2006). Therefore, patients with recurrent osteosarcoma presenting with a single pulmonary nodule more than 1 year after diagnosis may represent a group of patients with favourable outcome for whom chemotherapy does not add benefit. The goals of this study were to characterise the clinical features and outcome of these patients and to evaluate the role of chemotherapy in this setting.

PATIENTS AND METHODS

After obtaining approval from the Institutional Review Board of each participating institution, a retrospective medical record review was conducted at three institutions: Memorial Sloan-Kettering Cancer Center, St Jude Children’s Research Hospital (SJCRRH), and the Children’s Cancer Hospital of the University of Texas MD Anderson Cancer Center. Patients were considered eligible for this study if they were younger than 21 years of age at the time of initial diagnosis of non-metastatic high-grade osteosarcoma and had recurrence with only a single pulmonary metastasis more than 1 year after diagnosis that was confirmed by histology at the time of thoracotomy. Data collected included patient demographics, anatomic site of primary tumour, chemotherapy agents used during initial therapy, grade of histologic response to neoadjuvant therapy using the criteria described by Huvos (1991), time from diagnosis to recurrence, pulmonary nodule size, treatment at the time of recurrence, patient outcome, duration of follow-up, and cause of death. The date of relapse was defined as the time of thoracotomy for tumour removal.

Post-relapse survival (PRS) was defined as the time interval from the date of relapse to the date of death from any cause or the date of last contact for survivors. Post-relapse event-free survival (PREFS) was defined as the time interval from the date of relapse to the date of subsequent relapse or death from any cause or to the date of last contact for patients without subsequent events. PRS and PREFS were estimated using the method of Kaplan and Meier. Differences in distributions of PRS and PREFS among categorical variables were investigated using the exact log-rank test. Cox proportional hazards model was used to examine the association between continuous variables and outcome. Exact Wilcoxon rank-sum tests were used to examine the association between chemotherapy use at relapse with time to recurrence and nodule size.

RESULTS

Patient characteristics. A total of 39 patients satisfied the study inclusion criteria; their characteristics are summarised in Table 1. The median age at initial diagnosis was 14.6 years (range, 6.0–20.0 years). All patients were confirmed to have localised disease at the time of diagnosis. The femur was the most common primary site (N = 22; 56.4%).

| Primary site | N  | %   |
|--------------|----|-----|
| Femur        | 22 | 56.4|
| Tibia        | 12 | 30.8|
| Humerus      | 2  | 5.1 |
| Illium       | 2  | 5.1 |
| Radius       | 1  | 2.6 |

The number of chemotherapy agents used was as follows:

| Number of chemotherapy agents | N  | %   |
|------------------------------|----|-----|
| 0                            | 1  | 2.6 |
| 1                            | 1  | 2.6 |
| 2                            | 12 | 30.8|
| 3                            | 16 | 41  |
| 4                            | 10 | 25.6|

Histologic response:

|Histologic response | N  | %   |
|--------------------|----|-----|
| I                  | 3  | 7.7 |
| II                 | 13 | 41.9|
| III                | 5  | 16.1|
| IV                 | 5  | 16.1|
| PD                 | 2  | 6.5 |
| Data unavailable   | 3  | 7.7 |

Abbreviations: MSKCC = Memorial Sloan-Kettering Cancer Center; SJCRRH = St Jude Children’s Research Hospital; UTMDACC = University of Texas MD Anderson Cancer Center; PD = progressive disease.

10 days of diagnosis. For the 31 patients who did not have upfront surgery as part of their primary treatment, histologic responses were grade I (N = 3), grade II (N = 13), grade III (N = 5), and grade IV (N = 5); progressive disease occurred before surgery in 2 patients and no data was available for 3 patients.

Recurrence and treatment at recurrence. All patients had a thoracotomy; the median time from diagnosis to thoracotomy date (recurrence date) was 2.5 years (range, 1.2–8.2 years; Figure 1). The nodules occurred in the left (N = 22) or right (N = 17) lung. In 36 patients with available data, the median largest dimension of the pulmonary nodule was 1.5 cm (range, 0.5–18 cm). Twelve (31%) patients received chemotherapy at relapse.

Patient outcome. Twenty-three of 39 patients (59%) experienced a second recurrence, and 13 of these patients (57%) had a third recurrence or disease progression. Table 2 shows the timing of recurrence for patients who experienced disease recurrence. Twenty-one of 39 patients (54%) were alive at the time of analyses. The median follow-up duration from initial diagnosis was 12 years (range, 1.8–22.1 years). The median follow-up duration from the date of thoracotomy for survivors was 7.7 years (range, 0.6–20.9 years). Eighteen patients had no evidence of disease and three were alive with disease. The remaining 18 patients died of disease (N = 14) or other causes: acute myeloid leukaemia (N = 1), brain aneurysm (N = 1), sepsis (N = 1), and unknown cause (N = 1). The 5-year and 10-year estimates of PREFS were 33.0 ± 7.5% and 33.0 ± 9.6%, respectively, and of PRS 56.8 ± 8.6% and 53.0 ± 11.0%, respectively (Figure 2).
Prognostic factors. Table 3 summarises the results of investigating various factors as predictors of PRS and PREFS. None of the factors investigated were found to be significantly predictive of PRS. When investigated as a continuous variable, there was no evidence that time from diagnosis to relapse was significantly predictive of PRS (P = 0.123; hazard ratio, 0.75 (95% confidence interval, 0.53–1.08)). When investigated as a categorical variable (> 1 year to < 2 years vs ≥ 2 years to < 3 years vs ≥ 3 years to < 4 years vs ≥ 4 years after diagnosis), a trend was observed towards a positive predictive value for longer duration between diagnosis and relapse for PREFS (P = 0.062), but not for PRS (P = 0.31). When analysed as a continuous variable, nodule size was not significantly associated with PRS (P = 0.80; hazard ratio, 0.98). When studied as a categorical variable, a trend was observed between size < 1.5 cm and improved PREFS (P = 0.070), but not PRS (P = 0.49). Chemotherapy at first relapse did not affect PREFS (P = 0.84) or PRS (P = 0.54). Further analysis was performed to investigate whether there was any selection bias for patients who received chemotherapy at relapse with respect to nodule size and time to recurrence. There was no statistically significant difference for time to recurrence and nodule size between patients who received chemotherapy and those who did not (P > 0.11).

**DISCUSSION**

In this study, we analysed the treatment and outcome of 39 patients treated at three major cancer centres for osteosarcoma that recurred as a single pulmonary metastasis more than 1 year after diagnosis. All patients had thoracotomy and about one third received chemotherapy. The 10-year PREFS and PRS were 33.0 ± 9.6% and 53.0 ± 11.0%, respectively. These survival estimates compare favourably with those of patients with first relapse of osteosarcoma in general (10-year PREFS, 12% and 10-year PRS, 17–18%; Kempf-Bielack *et al*, 2005, Leary *et al*, 2013). Our study confirms that patients with recurrent osteosarcoma presenting as a single pulmonary nodule more than 1 year after diagnosis represent a favourable group of patients who can be cured by surgery alone. The use of chemotherapy at first relapse did not improve outcome.

In a retrospective review of 576 patients with relapsed osteosarcoma by the Cooperative Osteosarcoma Study Group (COSS), 80% of patients had lung metastasis and 65% of patients had lung metastasis as the only site of recurrence (Kempf-Bielack *et al*, 2005). Another review by the European Osteosarcoma Intergroup noted lung-only recurrence in 54% of the patients (Gelderblom *et al*, 2011). Although the long-term prognosis for patients with recurrent osteosarcoma remains poor, some progress has been made in identifying risk factors that can be used for patient stratification and tailoring salvage therapy. Hawkins and Arndt (2003) reported that for patients with initial pulmonary recurrence, the presence of solitary pulmonary nodules was associated with improved disease-free survival and OS. The COSS study demonstrated that bilateral pulmonary metastases and pleural disruption were poor prognostic factors (Kempf-Bielack *et al*, 2005). Leary *et al* (2013) reported that for patients with pulmonary relapse, unilateral disease and the presence of ≤ 3 nodules were favourable clinical factors.

Surgical resection of pulmonary metastases, whenever feasible, has been long considered standard treatment (Carter *et al*, 1991, van Geel *et al*, 1996, Harting *et al*, 2006). Disease-free interval following metastasectomy appears to be important for survival in recurrent osteosarcoma in the lung; one study noted a 3% decrease in mortality associated with each additional month of disease-free interval (Briccoli *et al*, 2005). Thoracotomy with wedge resection has been the preferred surgical approach for removal of lung nodules; a median sternotomy does not allow full exploration of the posterior pulmonary segments for nodules that may not have been radiologically evident. All patients in our study underwent thoracotomy for removal of the lung nodule. However, a recent study suggested that a minimally invasive approach to nodule removal with image-guided localisation, if needed, should be considered in patients with single pulmonary nodule because ipsilateral metastases are not likely to be found (Fernandez-Fineda *et al*, 2012).

The use of chemotherapy for patients with isolated pulmonary recurrence of osteosarcoma has been widely debated. One significant consideration for using a surgical-only treatment approach is to avoid the potential acute and late toxicities of chemotherapy. In the Hawkins and Arndt (2003) study, survival was superior among patients with pulmonary recurrence treated with surgery alone compared with patients treated with chemotherapy and surgery (47% vs 13%, P = 0.005). For patients with isolated pulmonary recurrence who achieved a second complete remission of disease, a trend towards improved survival rates for patients treated with surgery alone approached statistical significance (45% vs 13%, P = 0.08). However, the improved survival for patients treated with surgery alone likely reflects a biased use of chemotherapy in patients with incompletely resected disease. Ferrari *et al* (2003) reported that PRS was positively influenced by the use of second-line chemotherapy in patients who did not have complete surgery, but not in patients who had

---

**Table 2. Timing of recurrence**

| Time from diagnosis to RL1 | N    | Median | Range               |
|---------------------------|------|--------|---------------------|
| Time from thoracotomy to RL2 | 23   | 10.8 months | 1.8 months–3.8 years |
| Time from RL2 to RLPD3    | 13   | 5.2 months | 1.6 months–5.9 years |

**Abbreviations:** RL1 = first relapse; RL2 = second relapse; RLPD3 = third relapse or disease progression.
Table 3. Exploratory analyses of potential prognostic factors

| Factors                        | PRS ± s.e. (%) | PREFS ± s.e. (%) |
|--------------------------------|---------------|-----------------|
|                                | Year 5        | Year 10         | Year 5        | Year 10         | Year 5        | Year 10         | P     |
| Age at diagnosis               |               |                 |               |                 |               |                 |       |
| <16 years                      | 62.1 ± 10.2   | 56.4 ± 12.4     | 0.86          | 32.8 ± 9.0      | 32.8 ± 11.0   | 0.78            |       |
| ≥16 years                      | 46.3 ± 13.9   | 46.3 ± 19.6     |               | 33.3 ± 12.2     | 33.3 ± 15.7   |               |       |
| Gender                         |               |                 |               |                 |               |                 |       |
| Female                         | 57.7 ± 12.5   | 57.7 ± 14.2     | 0.93          | 40.4 ± 11.8     | 40.4 ± 13.9   | 0.49            |       |
| Male                           | 55.9 ± 11.2   | 49.7 ± 15.8     |               | 31.9 ± 10.7     | 31.9 ± 13.2   |               |       |
| Primary tumour site            |               |                 |               |                 |               |                 |       |
| Femur                          | 56.1 ± 10.7   | 49.9 ± 14.4     | 0.83          | 33.8 ± 9.7      | 33.8 ± 12.3   | 0.61            |       |
| Other bones                    | 58.2 ± 13.3   | 58.2 ± 15.4     |               | 31.9 ± 10.7     | 31.9 ± 13.2   |               |       |
| No. of active agents           |               |                 |               |                 |               |                 |       |
| <3 active agents               | 59.8 ± 13.4   | 49.9 ± 17.7     | 0.78          | 30.8 ± 11.4     | 30.8 ± 14.8   | 0.95            |       |
| ≥3 active agents               | 55.5 ± 10.7   | 55.5 ± 13.1     |               | 34.3 ± 9.3      | 34.3 ± 11.3   |               |       |
| Histologic response            |               |                 |               |                 |               |                 |       |
| Grade I or II or PD            | 46.4 ± 12.8   | 46.5 ± 15.2     | 0.73          | 20.0 ± 8.9      | 20.0 ± 10.3   | 0.80            |       |
| Grade III or IV                | 52.5 ± 16.2   | 52.5 ± 25.6     |               | 30.0 ± 12.5     | 30.0 ± 17.7   |               |       |
| Time to thoracotomy            |               |                 |               |                 |               |                 |       |
| ≥1 year to <2 years            | 43.1 ± 13.3   | 43.1 ± 14.5     | 0.31          | 22.2 ± 9.8      | 22.2 ± 9.8    | 0.062           |       |
| ≥2 years to <3 years           | 62.5 ± 15.6   | 46.9 ± 17.1     |               | 18.2 ± 9.5      | 18.2 ± 11.6   |               |       |
| ≥3 years to <4 years           | 50.0 ± 17.7   | 50.4 ± 25.0     |               | 33.3 ± 15.7     | 33.3 ± 19.2   |               |       |
| ≥4 years                       | 83.3 ± 13.9   | 83.3 ± 19.6     |               | 85.7 ± 13.2     | 85.7 ± 18.7   |               |       |
| Time to thoracotomy            |               |                 |               |                 |               |                 |       |
| <18 months                     | 42.9 ± 16.2   | 42.9 ± 16.2     | 0.97          | 30.0 ± 14.5     | 30.0 ± 14.5   | 0.93            |       |
| ≥18 months                     | 60.3 ± 9.5    | 55.2 ± 13.1     |               | 33.7 ± 8.3      | 33.7 ± 11.2   |               |       |
| Site of pulmonary nodule       |               |                 |               |                 |               |                 |       |
| Left lung                      | 54.7 ± 11.1   | 54.7 ± 16.5     | 0.95          | 34.1 ± 9.8      | 34.1 ± 13.8   | 0.66            |       |
| Right lung                     | 58.9 ± 12.6   | 51.6 ± 13.6     |               | 31.5 ± 10.6     | 31.5 ± 11.7   |               |       |
| Size of Pulmonary Nodule       |               |                 |               |                 |               |                 |       |
| <1.5 cm                        | 59.2 ± 12.6   | 50.8 ± 14.5     | 0.49          | 44.1 ± 11.7     | 44.1 ± 13.5   | 0.070           |       |
| ≥1.5 cm                        | 57.7 ± 11.9   | 57.7 ± 16.8     |               | 28.5 ± 9.8      | 28.5 ± 13.9   |               |       |
| Chemotherapy at first relapse  |               |                 |               |                 |               |                 |       |
| Yes                            | 50.9 ± 14.6   | 50.9 ± 17.8     | 0.54          | 37.5 ± 13.3     | 37.5 ± 17.1   | 0.84            |       |
| No chemotherapy                | 59.0 ± 10.1   | 54.1 ± 13.0     |               | 31.2 ± 8.6      | 31.2 ± 10.6   |               |       |

Abbreviations: PRS = post-relapse survival; PREFS = post-relapse event-free survival; PD = progressive disease.
relapse was 2.5 years, we could not further ascertain whether patients who present with a solitary pulmonary nodule recurrence may in fact represent a subset of relapsed patients with longer duration of disease-free interval, a known good prognostic factor. In the COSS study, a correlation was noted between solitary site of relapse and longer interval to relapse (Kempf-Bielack et al, 2005).

In conclusion, our multi-institutional study demonstrated that approximately half of the patients with recurrent osteosarcoma as a solitary pulmonary nodule more than 1 year after diagnosis were long-term survivors. Whether this improved outcome compared with that of patients with recurrent osteosarcoma in general could be related to low disease burden or favourable tumour biology remains to be determined. Our analyses did not reveal factors that help identify patients who are likely to survive or die, although there was a trend for improved outcome for those with smaller nodules or later relapse. It is hoped that clinical genomics or the ability to detect circulating sarcoma cells will help discern which patients will require further therapy in addition to surgery (Chen et al, 2014, Satelli et al, 2014). While the use of salvage chemotherapy did not confer a survival advantage in our study, perhaps novel therapies that are likely to be effective in the setting of minimal residual disease such as immunotherapy, will prove to be beneficial.

ACKNOWLEDGEMENTS

This work was supported in part by Cancer Centre Support (CORE) grant CA21765 and grant CA23099 from the National Cancer Institute and by the American Lebanese Syrian Associated Charities (ALSAC).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Bacci G, Briccoli A, Longhi A, Ferrari S, Mercuri M, Fagioli F, Versari M, Picci P (2005a) Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 44: 748–755.

Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P (2005b) Adjutant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer 41: 2836–2845.

Bacci G, Mercuri M, Longhi A, Ferrari S, Bertoni F, Versari M, Picci P (2005c) Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer 41: 2079–2085.

Briccoli A, Roccia M, Salone M, Bacci G, Ferrari S, Balladelli A, Mercuri M (2005) Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer 104: 1721–1725.

Carter S, Grimer R, Sneath R, Matthews HR (1991) Results of thoracotomy in osteogenic sarcoma with pulmonary metastases. Thorax 46: 727–731.

Chen X, Bahrami A, Pappo A, Easton J, Smethurst N, Eilson D, Shiu T, Wu G, Wei I, Parker M, Ruch C, Nagahawatte P, Wu J, Mao S, Boggis K, Mulder H, Yergeau D, Lu C, Ding L, Edmonson M, Qu C, Wang J, Li Y, Navid F, Daw N, Mardis E, Wilson R, Downing JR, Zhang J, Dyer M, St. Jude Children’s Research Hospital Washington University Pediatric Cancer Genome (2014) Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep 7: 104–112.

Chi S, Conklin L, Qin J, Meyers P, Huvos A, Healey J, Gorlick R (2004) The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 42: 46–51.

Crompton B, Goldsbry V, Weinberg V, Feren R, O'Donnell R, Ablin A (2006) Survival after recurrence of osteosarcoma: a 20-year experience at a single institution. Pediatr Blood Cancer 47: 255–259.

Fernandez-Pineda I, Daw N, McCarville B, Emanus L, Rao B, Davidoff A, Shochat S (2012) Patients with osteosarcoma with a single pulmonary nodule on computed tomography: a single-institution experience. J Pediatr Surg 47: 1250–1254.

Ferrari S, Briccoli A, Mercuri M, Bertoni F, Picci P, Tiengh A, Del Prever A, Fagioli F, Comandone A, Bacci G (2003) Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 21: 710–715.

Gelderbom H, Jinks R, Sydes M, Bramwell V, Van Glabbeke M, Grimer R, Hogendoorn P, MiTiernan A, Lewis I, Nooij M, Taminiu A, Whelan J (2011) Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EO) randomized controlled trials. Eur J Cancer 47: 895–902.

Harting M, Blakely M, Jaffe N, Cox J, Hayes-Jordan A, Benjamin R, Raymond A, Andressy R, Lally K (2006) Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg 41: 194–199.

Hawkins D, Arndt C (2003) Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 98: 2447–2456.

Huvos A (1991) Pathologic assessment of preoperative (neoadjuvant) chemotherapy. In Bone Tumors: Diagnosis, treatment, and prognosis. 2nd edn. W.B. Saunders: Philadelphia, PA, USA.

Kempf-Bielack B, Bielack S, Jurgens H, Branscheidt D, Berdel W, Eiener G, Gobel U, Helmke K, Jundt G, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, Treuner J, Zoubek A, Winkler K (2005) Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23: 559–568.

Leary S, Wozniak A, Billups C, Wu J, McPherson V, Neel M, Rao B, Daw N (2013) Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children’s Research Hospital experience. Cancer 119: 2645–2653.

Meyer W, Pratt C, PoQuette C, Rao B, Parham D, Marina N, Pappo A, Mahmoud H, Jenkins J, Harper J, Neel M, Fletcher B (2001) Carboplatin/Ifosfamide window therapy for osteosarcoma: results of the St. Jude Children’s Research Hospital OS91 trial. J Clin Oncol 19: 171–182.

Meyers P, Gorlick R, Heller G, Casper E, Lane J, Huvos A, Healey J (1998) Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16: 2452–2458.

Meyers P, Schwartz C, Krailo M, Kleinerman E, Betcher D, Bernstein M, Conrad E, Fergusson W, Gebhardt M, Goorin A, Harris M, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womar R, Grier H (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23: 2004–2011.

Satelli A, Mitra A, Cuterea J, Devarie M, Xia X, Ingram D, Dibra D, Somahia N, Torres K, Ravi V, Ludwig J, Kleinerman E, Li S (2014) Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res 74: 1645–1650.

van Geel A, Pastoreno U, Jauch K, Judson I, van Coevorden F, Buesa J, Nielsen O, Boudinet A, Tursz T, Schmitz P (1996) Surgical treatment of lung metastases: results of the Stude Children’s Research Hospital OS81 trial. Ann Oncol 19: 77–87.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.